{
    "clinical_study": {
        "@rank": "117808", 
        "acronym": "STAKT", 
        "arm_group": [
            {
                "arm_group_label": "AZD5363 480mg", 
                "arm_group_type": "Experimental", 
                "description": "AZD5363 480mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule"
            }, 
            {
                "arm_group_label": "AZD360mg", 
                "arm_group_type": "Experimental", 
                "description": "AZD5363  360mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule"
            }, 
            {
                "arm_group_label": "AZD5363 240mg", 
                "arm_group_type": "Experimental", 
                "description": "AZD5363 240mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the effect of four and a half days treatment of a range of doses of AZD5363 on\n      selected markers of the AKT pathway and anti-proliferation compared with placebo in\n      oestrogen receptor positive breast cancers.\n\n      To assess the tolerability of four and a half days treatment of AZD5363."
        }, 
        "brief_title": "AKT Inhibitor in Oestrogen Positive Breast Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Invasive Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The principal research questions to be addressed are whether (or not) AZD5363 is \"hitting\n      its therapeutic target\" sufficiently and to the extent that is required to produce efficacy\n      in pre-clinical experiments.\n\n      The primary endpoint markers have been selected to determine this.\n\n      Reductions in markers of the AKT pathway and increases in markers of anti-proliferation will\n      characterise the degree of biological activity arising from the inhibition of AKT across a\n      range of doses of AZD5363."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        WHO performance status 0-1 with no deterioration over the previous 2 weeks. Able to\n        swallow & retain oral medication. Post-menopausal. Female patients with histological\n        confirmation of ER positive invasive breast carcinoma.\n\n        Stage 1/2/3 or Stage 4 with primary tumour in the breast amenable to biopsies. Scheduled\n        to have chemotherapy (with or without surgery) based on tumour characteristics and local\n        treatment protocols.\n\n        Tumours large enough to provide sufficient tissue to be taken by core-cut or tru-cut\n        biopsy (free-hand or under ultrasound guidance as per local protocols) to provide tissue\n        sections for the marker assays.\n\n        -\n\n        Exclusion Criteria:\n\n        Any one of the following will exclude a patient from entering the trial:\n\n        Prior treatment for breast cancer. Treatment with HRT within 4 weeks prior to trial\n        treatment. Known ER negative tumour. Female patients with histological confirmation of ER\n        positive invasive breast carcinoma not scheduled to have chemotherapy (with or without\n        surgery) based on tumour characteristics and local treatment protocols.\n\n        Exposure to potent inhibitors or inducers of CYP3A4 or CYP2D6 or substrates of CYP3A4\n        within 2 weeks before the first dose of study treatment (3 weeks for St Johns Wort).\n\n        Clinically significant abnormalities of glucose metabolism as defined by any of the\n        following:    Diagnosis of diabetes mellitus type I or II;    Glycosylated haemoglobin\n        (HbA1C) >64 mmol/mol/8.0% at screening;    Fasting Plasma Glucose >7.0mmol/L at screening.\n\n        Major surgery (excluding placement of vascular access) within 4 weeks before the first\n        dose of study treatment.\n\n        Spinal cord compression or brain metastases. Evidence of severe or uncontrolled systemic\n        disease.\n\n        Any of the following cardiac criteria:\n\n        Mean resting corrected QT interval (QTc)>450 msec obtained from 3 consecutive ECGs;    Any\n        clinically important abnormalities in rhythm, conduction or morphology of resting ECG;\n        Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.\n\n        Any of the following procedures or conditions in the preceding 6 months: coronary artery\n        bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris,\n        congestive heart failure NYHA Grade 2.\n\n        Uncontrolled hypotension - SBP <90 mmHg and/or DBP <50 mmHg. Absolute neutrophil count\n        <1.5 x 10 /L. Platelet count <100 x 19 /L. Haemoglobin <90 g/L (<9g/dL / <5.59 mmol/L).\n        Alanine aminotransferase (ALT) >2.5 times ULN if no demonstrable liver metastases or >5\n        times ULN in the presence of liver metastases.\n\n        Elevated Alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone\n        metastasis and liver function is otherwise considered adequate in the investigator's\n        judgement.\n\n        Total bilirubin >1.5 times ULN if no liver metastases or >3 times ULN in the presence of\n        liver metastases.\n\n        Creatinine >1.5 times ULN concurrent with creatinine clearance <50 ml/min; confirmation of\n        creatinine clearance is only required when creatinine is >1.5 times ULN Proteinuria >3+ on\n        dipstick analysis. Refractory nausea and vomiting, chronic gastrointestinal diseases,\n        inability to swallow the formulated product or previous significant bowel resection that\n        would preclude adequate absorption of AZD5363.\n\n        History of hypersensitivity to active or inactive excipients of AZD5363 or drugs with a\n        similar chemical structure or class to AZD5363.\n\n        Current disease or condition known to interfere with absorption, distribution, metabolism\n        or excretion of drugs.\n\n        Past medical history of interstitial lung disease, drug induced interstitial lung disease,\n        radiation pneumonitis which required steroid treatment, or any evidence of clinically\n        active interstitial lung disease.\n\n        Evidence of dementia, altered mental status or any psychiatric condition that would\n        prohibit understanding or rendering of informed consent Previous allogeneic bone marrow\n        transplant. Immunodeficiency syndrome."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077569", 
            "org_study_id": "12076"
        }, 
        "intervention": {
            "arm_group_label": [
                "AZD5363 480mg", 
                "Placebo", 
                "AZD360mg", 
                "AZD5363 240mg"
            ], 
            "description": "Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses)", 
            "intervention_name": "AZD5363", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Estrogens"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "AKT inhibitor", 
            "AZD5363", 
            "Anti-tumour activity", 
            "Breast cancer", 
            "ER positive", 
            "Oestrogen positive", 
            "post menopausal", 
            "chemotherapy required", 
            "no prior cancer treatment"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "kl.cheung@nottingham.ac.uk", 
                    "last_name": "KL Cheung, MB", 
                    "phone": "0044 1332724881"
                }, 
                "facility": {
                    "address": {
                        "city": "Derby", 
                        "country": "United Kingdom", 
                        "state": "Derbyshire", 
                        "zip": "DE22 3DT"
                    }, 
                    "name": "Royal Derby Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "KL Cheung, MB", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "John FR Robertson, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "anthony.skene@rbch.nhs.uk", 
                    "last_name": "Anthony Skene, MS FRCS", 
                    "phone": "0044 1202303626"
                }, 
                "facility": {
                    "address": {
                        "city": "Bournemouth", 
                        "country": "United Kingdom", 
                        "state": "Dorset", 
                        "zip": "BH7 7DW"
                    }, 
                    "name": "Royal Bournemouth Hospital"
                }, 
                "investigator": {
                    "last_name": "Anthony Skene, MS FRCS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "abigail.evans@poole.nhs.uk", 
                    "last_name": "Abigail Evans, MD", 
                    "phone": "0044 1202442616"
                }, 
                "facility": {
                    "address": {
                        "city": "Poole", 
                        "country": "United Kingdom", 
                        "state": "Dorset", 
                        "zip": "BH15 2JB"
                    }, 
                    "name": "Poole Hospital NHS Foundation Trust"
                }, 
                "investigator": {
                    "last_name": "Abigail Evans, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "samreen.ahmed@uhl-tr.nhs.uk", 
                    "last_name": "Samreen Ahmed, MD", 
                    "phone": "0044 1162586295"
                }, 
                "facility": {
                    "address": {
                        "city": "Leicester", 
                        "country": "United Kingdom", 
                        "state": "Leicestershire", 
                        "zip": "LE1 5WW"
                    }, 
                    "name": "Leicester Royal Infirmary"
                }, 
                "investigator": {
                    "last_name": "Samreen Ahmed, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "anupam.modi@ulh.nhs.uk", 
                    "last_name": "Anupam M Modi, MD", 
                    "phone": "01522 512512", 
                    "phone_ext": "3259"
                }, 
                "facility": {
                    "address": {
                        "city": "Grantham", 
                        "country": "United Kingdom", 
                        "state": "Linconshire", 
                        "zip": "NG31 8DG"
                    }, 
                    "name": "Grantham District Hospital"
                }, 
                "investigator": {
                    "last_name": "Anupam K Modi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mike.dixon@ed.ac.uk", 
                    "last_name": "Mike Dixon, MD", 
                    "phone": "0044 1315372643"
                }, 
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom", 
                        "state": "Lothian", 
                        "zip": "EH4 2XU"
                    }, 
                    "name": "Western General Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Mike Dixon, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Oliver Young, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "chris.holcombe@rlbuht.nhs.uk", 
                    "last_name": "Chris Holcombe, MD", 
                    "phone": "0044 1517063459"
                }, 
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "United Kingdom", 
                        "state": "Merseyside", 
                        "zip": "L7 8XP"
                    }, 
                    "name": "Royal Liverpool University Hospital"
                }, 
                "investigator": {
                    "last_name": "Chris Holcombe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Mohamed.jahan@sfh-tr.nhs.uk", 
                    "last_name": "Mohamed A Jahan, MD", 
                    "phone": "01623 622 515", 
                    "phone_ext": "3960"
                }, 
                "facility": {
                    "address": {
                        "city": "Sutton-in-Ashfield", 
                        "country": "United Kingdom", 
                        "state": "Nottinghamshire", 
                        "zip": "NG17 4JL"
                    }, 
                    "name": "Kingsmill Hospital"
                }, 
                "investigator": {
                    "last_name": "Mohamed A Jahan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "r.e.coleman@sheffiled.ac.uk", 
                    "last_name": "Rob Coleman", 
                    "phone": "0044 1142265213"
                }, 
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom", 
                        "state": "South Yorkshire", 
                        "zip": "S10 2SJ"
                    }, 
                    "name": "Sheffield Cancer Research Centre"
                }, 
                "investigator": {
                    "last_name": "Rob Coleman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ejanemacaskill@nhs.net", 
                    "last_name": "Jane E MacAskill, MD", 
                    "phone": "0044 1382632565"
                }, 
                "contact_backup": {
                    "email": "a.m.thompson@dundee.ac.uk", 
                    "last_name": "Alastair M Thompson, MD", 
                    "phone": "0044 1382632565"
                }, 
                "facility": {
                    "address": {
                        "city": "Dundee", 
                        "country": "United Kingdom", 
                        "state": "Tayside", 
                        "zip": "DD1 9SY"
                    }, 
                    "name": "Ninewells Hopsital & Medical School"
                }, 
                "investigator": [
                    {
                        "last_name": "Jane E MacAskill, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Alastair M Thompson, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "d.w.rea@bham.ac.uk", 
                    "last_name": "Daniel Rae, MD", 
                    "phone": "0120 2303626"
                }, 
                "contact_backup": {
                    "email": "adele.francis@ehb.nhs.uk", 
                    "last_name": "Adele Francis, MD", 
                    "phone": "01213715036"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "state": "West Midlands", 
                        "zip": "B15 2TT"
                    }, 
                    "name": "University Hospital Birmingahm"
                }, 
                "investigator": [
                    {
                        "last_name": "Daniel Rea, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Adele Francis, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kieran.horgan@leedsth.nhs.uk", 
                    "last_name": "Keiran Horgan, MD", 
                    "phone": "0113 243 2799"
                }, 
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "state": "West Yorkshire", 
                        "zip": "LS9 7TF"
                    }, 
                    "name": "Leeds St James Institue of Oncology"
                }, 
                "investigator": {
                    "last_name": "Keiran Horgan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "The Short Term Effects of an AKT Inhibitor (AZD5363) on Biomarkers of the AKT Pathway and Anti-tumour Activity in a Breast Cancer Paired Biopsy Study", 
        "overall_contact": {
            "email": "john.robertson@nottingham.ac.uk", 
            "last_name": "John FR Robertson, MD", 
            "phone": "0044 1332724881"
        }, 
        "overall_official": {
            "affiliation": "University of Nottingham", 
            "last_name": "John FR Robertson, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Changes in pPRAS40, pGSK3b, Ki67", 
            "measure": "Primary endpoint: Pharmacodynamic biomarker analysis in tumour tissue to assess the biological effect of AZD5363 on markers of anti-proliferation and the AKT pathway", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 months: Stage 1 - 60 participants, up to 12 months.  Stage 1 biomarker analysis early in Stage 2.  Stage 2 proceeds where reduction in 1 of the  3 primary biomarkers.  Stage 2 - up to 90 participants, up to 16 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077569"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "By measuring biological changes in the tumour and circulation via measurement of changes in alternative biological markers which relate to the AKT pathway:\nTumour total and pAKT Tumour: cleaved caspase 3; pS6 (IHC); FOXO3a Blood (platelet-rich plasma): Total and pPRAS40; Total and pGSK3b; Total and pAKT.", 
                "measure": "Compare anti-proliferative effect on markers of the AKT pathway after 4&1/2days treatment at 3 different doses of AZD5363 vs placebo in Er +ve breast cancers", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 months. Stage 1: 60 participants in up to12 months.  Stage 2: 90 participants in up to 26 months."
            }, 
            {
                "description": "By measuring biological changes in the tumour and circulation via measurement of changes in alternative biological markers which relate to the AKT pathway:\nTumour total and pAKT Tumour: cleaved caspase 3; pS6 (IHC); FOXO3a Blood (platelet-rich plasma): Total and pPRAS40; Total and pGSK3b; Total and pAKT.", 
                "measure": "Compare direct effect on markers of the AKT pathway after 4&1/2days treatment at 3 different doses of AZD5363 vs placebo in Er +ve breast cancers", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 months. Stage 1: 60 participants in  up to12 months.  Stage 2: 90 participants in up to 26 months."
            }, 
            {
                "description": "Tolerability and toxicity will be measured following short term exposure to AZD5363 by incidence and severity of adverse events.\nParticipants will be monitored for adverse events during the study and for at least 30 days after the end of treatment.\nAnalysis of toxicity following the completion of Stage 1,  taking into consideration that Stage 2 will use lower doses of AZD5363, and at the end of Stage 2.", 
                "measure": "To measure tolerability and toxicity following short term (four and a half days) exposure to AZD5363", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 months. Stage 1: 60 participants in up to12 months.  Stage 2: 90 participants in up to 26 months."
            }
        ], 
        "source": "University of Nottingham", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "AstraZeneca", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Clinical Trials Awards and Advisory Committee", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Cancer Research Network", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Nottingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}